文献速递贫血与红细胞疾病血栓与止血白血病

AKT抑制剂在携带AKT1突变的实体瘤中的治疗研究

AKT Inhibition in Solid Tumors With AKT1 Mutations.
PubMed 文献 · J Clin Oncol · 2017-05-10

该多组织学篮式研究纳入58例晚期实体瘤患者,评估泛AKT激酶抑制剂AZD5363的初步活性。在52例AKT1 E17K突变患者中,中位无进展生存期为5.5个月(95%CI 2.9-6.9),常见≥3级不良事件为高血糖(24%)、腹泻(17%)和皮疹(15.5%)。研究首次提供AKT1 E17K可作为人类癌症治疗靶点的临床数据。

要点

  • AKT1 E17K突变实体瘤患者接受AZD5363治疗,中位无进展生存期5.5个月(95%CI 2.9-6.9)。
  • AKT1 E17K等位基因失衡与更长无进展生存期相关(HR 0.41,P=0.04)。
  • cfDNA中AKT1 E17K持续下降与改善的无进展生存期(HR 0.18,P=0.004)和缓解(P=0.025)相关。

核心结论

  • 本研究首次提供临床数据表明AKT1 E17K是人类癌症的治疗靶点,且该突变的基因组背景进一步影响了对AZD5363的应答。

研究设计与样本

  • 多组织学篮式研究,纳入58例晚期实体瘤患者接受AZD5363治疗,主要终点为安全性,次要终点为无进展生存期和根据RECIST的缓解。

主要发现

  • 在52例AKT1 E17K突变肿瘤患者(既往中位治疗线数为5线)中,中位无进展生存期在雌激素受体阳性乳腺癌、妇科肿瘤和其他实体瘤患者中分别为5.5个月(95%CI 2.9-6.9)、6.6个月(95%CI 1.5-8.3)和4.2个月(95%CI 2.1-12.8)。
  • 探索性生物标志物分析中,AKT1 E17K突变等位基因失衡(最常见由靶向野生型等位基因的拷贝中性杂合性缺失所致)与更长无进展生存期相关(HR 0.41,P=0.04),合并PI3K通路热点突变亦与更长无进展生存期相关(HR 0.21,P=0.045)。
  • cfDNA中AKT1 E17K持续下降与改善的无进展生存期(HR 0.18,P=0.004)和缓解(P=0.025)相关,且缓解不限于治疗前cfDNA中可检测到AKT1 E17K的患者。
  • 最常见的≥3级不良事件为高血糖(24%)、腹泻(17%)和皮疹(15.5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary activity of AKT inhibition in AKT-mutant cancers. Patients and Methods Fifty-eight patients with advanced solid tumors were treated. The primary end point was safety; secondary end points were progression-free survival (PFS) and response according to Response Evaluation Criteria in Solid Tumors (RECIST). Tumor biopsies and plasma cell-free DNA (cfDNA) were collected in the majority of patients to identify predictive biomarkers of response. Results In patients with AKT1 E17K-mutant tumors (n = 52) and a median of five lines of prior therapy, the median PFS was 5.5 months (95% CI, 2.9 to 6.9 months), 6.6 months (95% CI, 1.5 to 8.3 months), and 4.2 months (95% CI, 2.1 to 12.8 months) in patients with estrogen receptor-positive breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS (hazard ratio [HR], 0.41; P = .04), as was the presence of coincident PI3K pathway hotspot mutations (HR, 0.21; P = .045). Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS (HR, 0.18; P = .004) and response ( P = .025). Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA. The most common grade ≥ 3 adverse events were hyperglycemia (24%), diarrhea (17%), and rash (15.5%). Conclusion This study provides the first clinical data that AKT1 E17K is a therapeutic target in human cancer. The genomic context of the AKT1 E17K mutation further conditioned response to AZD5363.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hyman DM, Smyth LM, Donoghue MTA, et al. AKT Inhibition in Solid Tumors With AKT1 Mutations. J Clin Oncol. 2017. PMID: 28489509. doi:10.1200/JCO.2017.73.0143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。